» Articles » PMID: 24385344

Fatty Acid Nitroalkenes Ameliorate Glucose Intolerance and Pulmonary Hypertension in High-fat Diet-induced Obesity

Abstract

Aims: Obesity is a risk factor for diabetes and cardiovascular diseases, with the incidence of these disorders becoming epidemic. Pathogenic responses to obesity have been ascribed to adipose tissue (AT) dysfunction that promotes bioactive mediator secretion from visceral AT and the initiation of pro-inflammatory events that induce oxidative stress and tissue dysfunction. Current understanding supports that suppressing pro-inflammatory and oxidative events promotes improved metabolic and cardiovascular function. In this regard, electrophilic nitro-fatty acids display pleiotropic anti-inflammatory signalling actions.

Methods And Results: It was hypothesized that high-fat diet (HFD)-induced inflammatory and metabolic responses, manifested by loss of glucose tolerance and vascular dysfunction, would be attenuated by systemic administration of nitrooctadecenoic acid (OA-NO2). Male C57BL/6j mice subjected to a HFD for 20 weeks displayed increased adiposity, fasting glucose, and insulin levels, which led to glucose intolerance and pulmonary hypertension, characterized by increased right ventricular (RV) end-systolic pressure (RVESP) and pulmonary vascular resistance (PVR). This was associated with increased lung xanthine oxidoreductase (XO) activity, macrophage infiltration, and enhanced expression of pro-inflammatory cytokines. Left ventricular (LV) end-diastolic pressure remained unaltered, indicating that the HFD produces pulmonary vascular remodelling, rather than LV dysfunction and pulmonary venous hypertension. Administration of OA-NO2 for the final 6.5 weeks of HFD improved glucose tolerance and significantly attenuated HFD-induced RVESP, PVR, RV hypertrophy, lung XO activity, oxidative stress, and pro-inflammatory pulmonary cytokine levels.

Conclusions: These observations support that the pleiotropic signalling actions of electrophilic fatty acids represent a therapeutic strategy for limiting the complex pathogenic responses instigated by obesity.

Citing Articles

Obesity-related Asthma: A Pathobiology-based Overview of Existing and Emerging Treatment Approaches.

Althoff M, Gaietto K, Holguin F, Forno E Am J Respir Crit Care Med. 2024; 210(10):1186-1200.

PMID: 39311907 PMC: 11568442. DOI: 10.1164/rccm.202406-1166SO.


Skeletal Muscle SIRT3 Deficiency Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction.

Jheng J, Bai Y, Noda K, Huot J, Cook T, Fisher A Circulation. 2024; 150(11):867-883.

PMID: 38804138 PMC: 11384544. DOI: 10.1161/CIRCULATIONAHA.124.068624.


Celebrating Versatility: Febuxostat's Multifaceted Therapeutic Application.

Kraev K, Geneva-Popova M, Hristov B, Uchikov P, Popova-Belova S, Kraeva M Life (Basel). 2023; 13(11).

PMID: 38004339 PMC: 10672185. DOI: 10.3390/life13112199.


A nitroalkene derivative of salicylate alleviates diet-induced obesity by activating creatine metabolism and non-shivering thermogenesis.

Cal K, Leyva A, Rodriguez-Duarte J, Ruiz S, Santos L, Colella L Res Sq. 2023; .

PMID: 37502859 PMC: 10371099. DOI: 10.21203/rs.3.rs-3101395/v1.


Cardiometabolic Risk Factors Associated With Right Ventricular Function and Compensation in Patients Referred for Echocardiography.

Morrison A, Huang S, Annis J, Garry J, Hemnes A, Freiberg M J Am Heart Assoc. 2023; 12(12):e028936.

PMID: 37301756 PMC: 10356017. DOI: 10.1161/JAHA.122.028936.


References
1.
Coles B, Bloodsworth A, Clark S, Lewis M, Cross A, Freeman B . Nitrolinoleate inhibits superoxide generation, degranulation, and integrin expression by human neutrophils: novel antiinflammatory properties of nitric oxide-derived reactive species in vascular cells. Circ Res. 2002; 91(5):375-81. DOI: 10.1161/01.res.0000032114.68919.ef. View

2.
Huertas A, Tu L, Gambaryan N, Girerd B, Perros F, Montani D . Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. Eur Respir J. 2012; 40(4):895-904. DOI: 10.1183/09031936.00159911. View

3.
Quarck R, Nawrot T, Meyns B, Delcroix M . C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 53(14):1211-8. DOI: 10.1016/j.jacc.2008.12.038. View

4.
Hansmann G, Wagner R, Schellong S, de Jesus Perez V, Urashima T, Wang L . Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation. 2007; 115(10):1275-84. DOI: 10.1161/CIRCULATIONAHA.106.663120. View

5.
Robbins I, Newman J, Johnson R, Hemnes A, Fremont R, Piana R . Association of the metabolic syndrome with pulmonary venous hypertension. Chest. 2009; 136(1):31-36. PMC: 2716716. DOI: 10.1378/chest.08-2008. View